Evidence map›Paper›PMID 41454501›Full record

ArticlePolish journal of microbiology2025

Antimicrobial Resistance Profiles of

Hyo-Jin Lee, Sung-Yeon Cho, Dong-Gun Lee, Chulmin Park, Jihyun Byun, Hye-Sun Chun, Yang Ree Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Polish journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyo-Jin LeeDivision of Infectious Diseases, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Sung-Yeon ChoDivision of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Dong-Gun LeeDivision of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Chulmin ParkVaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Jihyun ByunVaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hye-Sun ChunVaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yang Ree KimDivision of Infectious Diseases, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug Resistance, Multiple, BacterialPseudomonas aeruginosaPseudomonas InfectionsBacterial Proteinsbeta-LactamasesColistinDrug CombinationsHumansMicrobial Sensitivity TestsRepublic of KoreaAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCeftazidimeColistinDrug Combinationsavibactamceftazidimedrug resistancePseudomonas aeruginosaresidence characteristics

Identifiers

PMID41454501
PMCPMC12743181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.